ivWatch Partners with National Infusion Center Association (NICA)

ivWatch, LLC, the IV safety company, today announced that it has partnered with the National Infusion Center Association (NICA), an independent, nonprofit trade association and accrediting body dedicated to representing ambulatory outpatient care settings where provider-administered biologics and specialty medications are prepared and administered.

In alignment, ivWatch and NICA are partnering with an emphasis on providing innovative and accessible solutions to freestanding infusion centers and their patients. The proprietary patient monitoring technology from ivWatch allows patients to have continuous IV site monitoring during infusions in the comfort and convenience of an outpatient setting.

“NICA has been the nation’s voice for independent infusion centers for more than a decade, overcoming countless barriers to care and access obstacles on behalf of patients and dedicated to ensuring that the nation’s infusion centers remain a safe, efficient, and cost-effective means of receiving consistent, high-quality care,” notes Brian Nyquist, MPH, NICA President and CEO. “We are excited to have ivWatch on board in 2024 as our trusted partner in helping our industry remain on the cutting edge of patient safety innovation.”

“Infusion centers are on the frontlines of IV patient safety, so this partnership is a natural fit,” says Erin Wendell, chief marketing officer at ivWatch. “It is also a perfect opportunity to work with this fast-growing segment of the healthcare industry in advocating for the increased adoption that a monitoring technology can play in reducing the severity of IV injuries while also mitigating the liability risks associated with IV extravasation and infiltration.”

This partnership comes at a monumental time of global adoption for ivWatch, as the company expands its reach to patients in all care areas that provide essential infusions. The company recently filed for 510(k) clearance for iron-based infusions to better protect patients not only from IV injuries but also the specific lifelong effects of irreversible skin staining that occurs with iron extravasations.

NICA and ivWatch will collaborate on several educational webinars relevant to infusion centers, including the recognition and interventions of early stages of IV extravasations to help promote safer delivery of IV therapy. The company will also exhibit at NICA’s annual conference on June 21-22, 2024, at the MGM Grand in Las Vegas in Booth 207. ivWatch will be a key participant at the exclusive NICA Infusion Center of Excellence (NICE) Experience, which provides an insider look at the ideal infusion center model. Products and technologies that improve patient care and promote patient safety will be displayed prominently. The event will provide a firsthand immersive experience for clinicians, administrators, managers, and owners.


Learn more here.

Recent News


ivWatch prevents IV leakage events at Frimley Health

Frimley Health NHS Foundation Trust has found that 100% of IV leakage incidents were prevented by a proprietary patient monitoring system from ivWatch, which could potentially save patients the pain or discomfort of adverse IV events. The initial two-week phase of the study, which was published in the British Journal of Nursing, found that continuous


U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to develop the latest generation pralidoxime chloride auto-injector as a countermeasure against organophosphate or nerve agent poisoning.


Activation Capital Welcomes Dr. Jim Pannucci as its Vice President of Entrepreneurship

Activation Capital, an innovation ecosystem development organization, announced today that it has appointed Jim Pannucci, Ph.D., PMP as its Vice President of Entrepreneurship. As the new Vice President of Entrepreneurship, Dr. Pannucci will help Activation Capital continue to grow a deep talent base of life sciences entrepreneurs operating in the region and help empower them